In:
Pediatric Transplantation, Wiley, Vol. 22, No. 3 ( 2018-05)
Abstract:
ECP is an established “second‐line” treatment for CLAD / BOS . Recently, ECP was used for the first time in an adolescent CF patient as a “second‐line” treatment therapy in life‐threatening primary graft dysfunction following lung transplantation who deteriorated despite extensive treatment including ECMO and ATG . Within 10 days after initiation of ECP twice weekly, allograft function and clinical status improved significantly and the patient was weaned from mechanical ventilation support . ECP has been continued every 2 weeks since. Two hundred days after lung transplantation, the patient has an acceptable allograft function ( FEV 1 67%) and no signs of allograft rejection. We advocate that use of ECP and its immunomodulatory effects should be evaluated in the early period following lung transplantation.
Type of Medium:
Online Resource
ISSN:
1397-3142
,
1399-3046
DOI:
10.1111/petr.2018.22.issue-3
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2008614-3
